VIPR1 and neoplasm: In all mice bearing either MT5, KPC-Luc, or Panc02 tumors, the combination of VIP-R antagonist with anti-PD-1 significantly decreased tumor burden (Supplementary Fig. 6a–c) and improved survival when compared to mice treated with scrambled peptide and isotype matched IgG (Fig. 3a, b).